Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
about
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance TestingPharmacy refill data can be used to predict virologic failure for patients on antiretroviral therapy in Brazil.Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe
P2860
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Boosted lopinavir- versus boos ...... uals in high-income countries.
@ast
Boosted lopinavir- versus boos ...... uals in high-income countries.
@en
type
label
Boosted lopinavir- versus boos ...... uals in high-income countries.
@ast
Boosted lopinavir- versus boos ...... uals in high-income countries.
@en
prefLabel
Boosted lopinavir- versus boos ...... uals in high-income countries.
@ast
Boosted lopinavir- versus boos ...... uals in high-income countries.
@en
P2093
P2860
P50
P356
P1476
Boosted lopinavir- versus boos ...... uals in high-income countries.
@en
P2093
Andrew Phillips
Anna Esteve
Ashley Olson
Giota Touloumi
HIV-CAUSAL Collaboration
James M Robins
James Young
Janet Tate
Jonathan A C Sterne
P2860
P304
P356
10.1093/CID/CIU1167
P407
P50
P577
2015-01-06T00:00:00Z